1 week Ago By ABMN Staff
Lexeo Therapeutics ( NASDAQ:LXEO – Get Free Report ) and AlloVir ( NASDAQ:ALVR – Get Free Report ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings. Insider & Institutional Ownership 60.7% of Lexeo Therapeutics shares are held by institutional investors.
Comparatively, 66.1% of AlloVir shares are held by institutional investors. 4.
5% of Lexeo Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders.
Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Profitability This table compares Lexeo Therapeutics and AlloVir’s net margins, return on equity and return on assets. Analyst Recommendations Lexeo Therapeutics presently has a consensus target price of $23.
80, indicating a potential upside of 256.82%. Given Lexeo Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Lexeo Therapeutics is more favorable than AlloVir.
Valuation and Earnings This table compares Lexeo Therapeutics and AlloVir”s revenue, earnings per share (EPS) and valuation. Lexeo Therapeutics has higher revenue and earnings than AlloVir. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Summary Lexeo Therapeutics beats AlloVir on 8 of the 12 factors compared between the two stocks. About Lexeo Therapeutics ( Get Free Report ) Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
About AlloVir ( Get Free Report ) Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc.
in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
